Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 15/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 7/20 | 0.44 |
| ▸ | PRKACA | P17612 | 4/20 | 0.44 |
| ▸ | PRKACG | P22612 | 4/20 | 0.44 |
| ▸ | PRKACB | P22694 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107424 | 0.84 | LIMK2 (0.45) | LIMK2LIMK1PRKACAPRKACGPRKACB | |
| SCHEMBL10107567 | 0.79 | LIMK2 (0.57) | LIMK2LIMK1PRKACAPRKACGPRKACB | |
| SCHEMBL10107430 | 0.79 | LIMK2 (0.56) | LIMK2LIMK1PRKACAPRKACGPRKACB | |
| SCHEMBL4296833 | 0.78 | LIMK2 (0.80) | LIMK2LIMK1PRKACAPRKACGPRKACB | |
| SCHEMBL14073730 | 0.73 | LIMK2 (0.58) | LIMK2KDM4EMEN1TP53TSHR | |
| SCHEMBL13951179 | 0.71 | LIMK2 (0.70) | LIMK2KITLIMK1ROCK2ROCK1 | |
| SCHEMBL1166738 | 0.70 | ALDH1A1 (0.58) | TP53TSHRKMT2A | |
| SCHEMBL4302014 | 0.69 | LIMK2 (0.59) | LIMK2KITLIMK1PRKACAPRKACG | |
| SCHEMBL4294262 | 0.68 | LIMK2 (1.00) | LIMK2LIMK1PRKACAPRKACGPRKACB | |
| SCHEMBL4290392 | 0.68 | LIMK2 (0.62) | LIMK2LIMK1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193202-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | LIMK2 1/4885KIT 2104/4885LIMK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.